NCT06989814 Smart Measurement of Circulating Tumor DNA
| NCT ID | NCT06989814 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Erasmus Medical Center |
| Condition | Colorectal Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-05-16 |
| Primary Completion | 2026-10-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The goal of this study is to develop a blood-test which can detect colorectal cancer in early stages. Participants will be asked to take an extra blood test, which will be analyzed further in the lab.
Eligibility Criteria
Inclusion Criteria: (suspect) Lynch Syndrome carriers who: * Have proven Lynch Syndrome (MMR-gene or EPCAM mutation), or have a proven microsatellite instability high (MSI-H)tumor; * Are at least 18 years old; Have been diagnosed with any form of cancer at the time of inclusion, but have had no treatment yet; * Have granted informed consent to participate in this study. Exclusion Criteria: (suspect) Lynch Syndrome carriers who: * Are unwilling to undergo extra blood sampling; * Are under the age of 18; * Have no newly diagnosed tumors at time of inclusion; * Have been treated for their tumor at time of inclusion; * Are not able to read or understand Dutch language or are mentally not capable.